Last $4.75 USD
Change Today +0.11 / 2.37%
Volume 655.7K
ARRY On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 4:00 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

array biopharma inc (ARRY) Snapshot

Open
$4.68
Previous Close
$4.64
Day High
$4.79
Day Low
$4.64
52 Week High
01/22/14 - $5.64
52 Week Low
10/13/14 - $2.98
Market Cap
626.8M
Average Volume 10 Days
2.1M
EPS TTM
$-0.76
Shares Outstanding
132.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARRAY BIOPHARMA INC (ARRY)

array biopharma inc (ARRY) Related Bloomberg News

View More Bloomberg News

array biopharma inc (ARRY) Related Businessweek News

No Related Businessweek News Found

array biopharma inc (ARRY) Details

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. Its proprietary clinical programs in Phase II clinical trial include ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease. The company’s proprietary programs also comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; and ARRY-614, a p38/Tie2 dual inhibitor for myelodysplastic syndromes. Its partnered clinical programs include various drug candidates, including Binimetinib, an MEK inhibitor for cancer; Selumetinib, an MEK inhibitor for cancer; ASLAN001/ARRY-543, an HER2/EGFR inhibitor for gastric cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; VTX-2337, a toll-like receptor for cancer; and Danoprevir, a Hepatitis C virus protease inhibitor. The company’s partnered clinical programs also comprise LY2606368, an Chk-1 inhibitor for cancer; GDC-0575, an Chk-1 inhibitor for cancer; ARRY-380/ONT-380, an HER2 inhibitor for breast cancer,; GDC-0994, an ERK inhibitor for cancer; and LOXO-101, an PanTrk inhibitor for cancer. It has collaborations with Celgene Corporation; Celgene Alpine Investment Co., LLC; Genentech, Inc.; Loxo Oncology, Inc; Novartis International Pharmaceutical Ltd.; and Oncothyreon Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

198 Employees
Last Reported Date: 08/15/14
Founded in 1998

array biopharma inc (ARRY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $548.8K
Co-Founder, Chief Operating Officer and Vice ...
Total Annual Compensation: $388.6K
Chief Financial Officer
Total Annual Compensation: $358.1K
Vice President, General Counsel and Secretary
Total Annual Compensation: $357.5K
Senior Vice President of Commercial Operation...
Total Annual Compensation: $343.8K
Compensation as of Fiscal Year 2014.

array biopharma inc (ARRY) Key Developments

Array to Regain Worldwide Rights for Cancer Drug from Novartis

Array BioPharma Inc. has announced a definitive agreement with Novartis International Pharmaceutical Ltd. to regain worldwide rights to binimetinib, a MEK inhibitor in three Phase III cancer trials. Terms of the Agreement Upon deal close, Array will receive up to $85 million and Novartis' global, exclusive license to binimetinib will terminate with all rights reverting to Array. Novartis has agreed to provide transitional regulatory, clinical development and manufacturing services as specified below and will assign to Array patent and other intellectual property rights it owns to the extent relating to binimetinib. All clinical trials involving binimetinib, including the COLUMBUS, NEMO and MILO pivotal trials, will continue to be conducted as currently contemplated. Novartis will be responsible for continued conduct and funding of the COLUMBUS trial. This obligation will transfer to any future owner of LGX818 (encorafenib). Following deal close, Novartis will reimburse Array for all remaining out-of-pocket expenses and half of all remaining fully-burdened full time equivalent (FTE) costs associated with MILO, which Array will continue to conduct. For NEMO and all other ongoing and planned clinical trials, Novartis will conduct and solely fund each trial, until a mutually agreed-upon transition date to Array. Following this transition, Novartis will reimburse Array for all remaining out-of-pocket expenses and half of all remaining fully-burdened FTE costs required to complete these studies. Novartis will remain responsible for conducting and funding development of the NRAS melanoma companion diagnostic until Premarket Approval is received from the FDA. Following approval, Novartis will transfer the product and Premarket Approval to a diagnostic vendor of Array's designation. Novartis also retains binimetinib supply obligations for all clinical and commercial needs for up to 30 months after closing and will also assist Array in the technology and manufacturing transfer of binimetinib. Novartis will also provide Array continued access to several Novartis pipeline compounds including, but not limited to, LEE011 (CDK 4/6 inhibitor) andBYL719 (a-PI3K inhibitor), for use in currently ongoing combination studies, and possible future studies, including Phase III trials, with binimetinib.

Oncothyreon Announces Exclusive License Agreement With Array BioPharma for ONT-380

Oncothyreon Inc. announced that Array BioPharma Inc. has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor. The license agreement replaces the prior Development and Collaboration Agreement under which Oncothyreon and Array were jointly developing ONT-380. As part of the agreement, Oncothyreon will pay Array $20 million as an upfront fee. In addition, Oncothyreon will pay Array a significant portion of any payments received from sublicensing ONT-380 rights. If Oncothyreon is acquired within three years of the effective date of the current agreement, Array will be eligible for up to $280 million in commercial milestone payments. Array is also entitled to receive up to a double-digit royalty based on net sales of ONT-380.

Array BioPharma, Inc. - Special Call

To discuss a definitive agreement with Novartis International Pharmaceutical Ltd. to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARRY:US $4.75 USD +0.11

ARRY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $3.42 USD -0.15
CTI BioPharma Corp $2.40 USD +0.04
Evotec AG €3.65 EUR -0.042
Exelixis Inc $1.33 USD +0.04
Progenics Pharmaceuticals Inc $7.24 USD +0.25
View Industry Companies
 

Industry Analysis

ARRY

Industry Average

Valuation ARRY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARRAY BIOPHARMA INC, please visit www.arraybiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.